Using a new drug combination to fight malaria resistance
Official title: Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance
Funded at Weill Medical Coll of Cornell Univ · NIH-10878884 · Data updated 2026-11-12
This study is testing a new drug called artezomib to see if it can help treat malaria, especially in young children, by working better against the malaria parasite that has become resistant to current medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $735,318 |
| NIH project number | 5R01AI177635-02 |
| Project ID | NIH-10878884 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old who are diagnosed with malaria, particularly those with drug-resistant strains.
✕Less likely to help
Patients with malaria who are not affected by drug resistance or who are older than 11 years may not benefit from this research.
What this research studies
This research investigates a novel approach to combat malaria by targeting the Plasmodium falciparum parasite, which has developed resistance to current treatments. The study focuses on a new drug called artezomib (ATZ), which combines an artemisinin analogue with a proteasome inhibitor to enhance the effectiveness of existing malaria therapies. By understanding how this drug works at a cellular level, researchers aim to improve treatment outcomes for patients, particularly young children who are most affected by malaria. The research involves laboratory experiments to test the efficacy of ATZ against various strains of the parasite, including those resistant to standard treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for malaria, reducing the disease's impact on young children and vulnerable populations.
How similar studies have gone: Previous research has shown promise in using proteasome inhibitors in combination with existing malaria treatments, indicating a potential for success with this novel approach.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Lin, Gang — Weill Medical Coll of Cornell Univ
- Study coordinator: Lin, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.